11-11/12 :: November/December 2011

nanotimes

Companies Facts

aspects of the development program to support a (European) Marketing Authorisation Application (MAA) for VivaGel®

form and position the company very strongly for the future.”

for the treatment of BV. Follow-

ing these discussions, Starpharma now has reached agreement on Phase 3 clinical trial design with the regulatory authorities for both the US and Europe. The significance of the EMA feedback is that Star- pharma has now confirmed for both major global markets – Europe and the US – that its Phase 3 pro- gram is acceptable, and positive results (as recently achieved for the Phase 2) would support approval of the product.

Moreover, Starpharma announced that its Share Purchase Plan (SPP) which closed on Wednesday December 07, 2011, is oversubscribed by more than 400%. The SPP was capped at $3 million, and shareholders have subscribed a total in excess of $12 million. The SPP follows a placement in November to international and domestic institutional, sophisticated and professional investors which raised A$32 million. The SPP and placement were conducted at the last closing price prior to Trading Halt on 14 November (A$1.075 per share). There was strong participation in the placement from existing investors and it was led by the large UK based global fund M&G, which acquired a 6.7% stake in the Company. As a result of the strong demand and oversubscription of the SPP, applications will need to be scaled back, and refunds will be issued following allotment of the new shares.

Starpharma Chief Executive Officer Dr Jackie Fairley said: “We are delighted to see such strong demand shown in the recent financing and we thank our shareholders for their tremendous support. These funds will allow us to significantly accelerate multiple products based on our dendrimer technology plat-

http://www.starpharma.com T ecnan-Nanomat presented new products:

• Zirconium (50%) and Cerium (50%) mixed oxide nanoparticles dopped with Platinum (2%), available formats: container of 100 g, 500 g and 1 kg (weight of delivered nanopowder);

• Zirconium and Cerium mixed oxide nanoparticles (30% w/w CeO2

), available formats: container of

100 g, 500 g and 1 kg (weight of delivered nano- powder);

• Zirconium oxide nanoparticles dopped 16% with Yttria - Yttium Stabilized zirconia (YSZ), available formats: container of 100 g, 500 g and 1 kg;

• Zirconium (50%) and Cerium (50%) mixed oxide nanoparticles dopped with Paladium (2%), available formats: container of 100 g, 500 g and 1 kg.

http://www.tecnan-nanomat.es T

egal Corporation (NASDAQ:TGAL) has made a $300,000 strategic investment in NanoVibro-

nix Inc., a private company that develops medical devices and products that implement its proprietary therapeutic ultrasound technology.

NanoVibronix is a medical device company focused on creating products utilizing its proprietary low- intensity surface acoustic wave (SAW) technology. The company‘s unique, patented approach enables

29